Yıldız, YeşimÖzger, Hasan SelçukAcar, AliKeskin, Ayşegül SeremetBinay, Umut DevrimÜnlü, GültenDiseases, The Adult Immunization Study Group Of The Turkish Society Of Clinical Microbiology And InfectiousBasic Sciences2024-07-052024-07-05202302667-646X2667-646X10.36519/idcm.2023.216https://doi.org/10.36519/idcm.2023.216https://search.trdizin.gov.tr/tr/yayin/detay/1183916/the-impact-of-vaccination-among-hospitalized-patients-with-the-diagnosis-of-covid-19Azap, Alpay/0000-0001-5035-055X; binay, umut devrim/0000-0003-3841-9109; mete, ayşe özlem/0000-0003-0994-4465; ÜNLÜ, GÜLTEN/0000-0002-1260-5109; bayram, halim/0000-0002-0023-0645; Karamanlioglu, Dilek/0000-0002-8160-8231; Ozger, H.Selcuk/0000-0003-3894-0092Objective: We aimed to investigate the vaccination status and the risk factors for the in- tensive care unit (ICU) support need of the laboratory-confirmed breakthrough COVID-19 infection inpatients. Materials and Methods: This multi-center point-prevalence study was conducted on inpa- tients, divided into two groups as ‘fully’ and ‘partially’ vaccinated according to COVID-19 vaccination status. Results: Totally 516 patients were included in the study. The median age was 65 (55-77), and 53.5% (n=276) of the patients were male. Hypertension (41.9%, n=216), diabetes mel- litus (DM) (31.8%, n=164), and coronary artery disease (CAD) (16.3%, n=84) were the pre- dominant comorbidities. Patients were divided into two groups ICU (n=196) and non-ICU (n=301). Hypertension (p=0.026), DM (p=0.048), and congestive heart failure (CHF) (p=0.005) were significantly higher in ICU patients and the median age was younger among non-ICU patients (p=0.033). Of patients, 16.9% (n=87) were fully vaccinated, and this group’s need for ICU support was statistically significantly lower (p=0.021). Conclusion: We conclude that older age, hypertension, DM, CHF, and being partially vacci- nated were associated with the need for ICU support. Therefore, all countries should con- tinuously monitor post-vaccination breakthrough COVID-19 infections to determine the national booster vaccine administration approach that will provide vulnerable individuals the highest protection.eninfo:eu-repo/semantics/openAccessArticleN/A52118126WOS:001138794000007386330111183916